(Q53535031)

English

Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer.

scientific article published in November 1999

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10612010

0 references

Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10612010

1 reference

based on heuristic

inferred from title

quality of life

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Lachaine J

1

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10612010

Laurier C

2

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10612010

Langleben A

3

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10612010

Vaillant L

4

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10612010

publication date

1 November 1999

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10612010

Critical Reviews in Oncology Hematology

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10612010

32

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10612010

2

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10612010

105-112

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10612010

On the receiving end--patient perception of the side-effects of cancer chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900025-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900025-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900025-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The real costs of emesis--an economic analysis of ondansetron vs. metoclopramide in controlling emesis in patients receiving chemotherapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900025-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Low dose ondansetron and dexamethasone: a cost effective alternative to high dose metoclopramide/dexamethasone/lorazepam in the prevention of acute cisplatin induced emesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900025-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Ondansetron: costs and resource utilisation in a US teaching hospital setting

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900025-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Ondansetron: a cost-effective advance in anti-emetic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900025-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised, double-blind, parallel-group study to compare the efficacy and safety of ondansetron (GR38032F) plus dexamethasone with metoclopramide plus dexamethasone in the prophylaxis of nausea and emesis induced by carboplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900025-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900025-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900025-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900025-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life studies in chemotherapy-induced emesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900025-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of twice daily versus three times daily oral ondansetron in the prevention of chemotherapy induced emesis: a randomized, single-blind, multicentre study. The Ondansetron International Emesis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900025-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The effectiveness of a single intravenous dose of ondansetron

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900025-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1040-8428(99)00025-6

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10612010

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10612010

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53535031&oldid=1772551933"